Drug Trial Radar · NCT02299999
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,460
Actual
Start
Apr 7, 2014
Primary completion
Dec 2022
Study completion Dec 2025
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fondation ARC; AstraZeneca
- First posted
- Nov 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with maintenance chemotherapy (targeted substudy 1) as well as immunotherapy with maintenance chemotherapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
Conditions
- Metastatic Breast Cancer
Interventions
AZD2014Drug
Target: m-TOR
AZD4547Drug
Target: EGFR
AZD5363Drug
Target: AKT
AZD8931Drug
Target: HER2, EGFR
SelumetinibDrug
Target: MEK
VandetanibDrug
Target: VEGF, EGFR
BicalutamideDrug
target: Androgen receptor
OlaparibDrug
Target: PARP
AnthracyclinesDrug
DNA intercalation
TaxanesDrug
Target: mitotic tubulin and microtubules
cyclophosphamideDrug
Alkylating agents
DNA intercalatorsDrug
DNA intercalators
MethotrexateDrug
DNA intercalators
vinca alkaloidsDrug
Target: mitotic tubulin and microtubules
Platinum based chemotherapiesDrug
Platinum based chemotherapies
BevacizumabDrug
Target: VEGF
Mitomycin CDrug
Alkylating agents
EribulinDrug
Microtubule modulator
MEDI4736Drug
Target: PD-L1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival in the targeted drug arm compared to standard maintenance therapy armTime frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Institut de Cancérologie de l'Ouest/Paul Papin
Angers, France
Institut Sainte-Catherine
Avignon, France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Georges François Leclerc
Dijon, France
Chd Vendee
La Roche-sur-Yon, France
Centre Oscar Lambret
Lille, France
Chu Dupuytren
Limoges, France
Centre Hospitalier Lyon Sud
Lyon, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Institut Régional du Cancer Montpellier Val d'Aurelle
Montpellier, France
Centre Alexis Vautrin
Nancy, France
Institut de Cancérologie de l'Ouest/ René Gauducheau
Nantes, France
Centre Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
Centre Eugène Marquis
Rennes, France
Centre Henri Becquerel
Rouen, France
Institut Curie
Saint-Cloud, France
Hopitaux Universitaire de Strasbourg - Hopital Civil
Strasbourg, France
Hopitaux Du Leman
Thonon-les-Bains, France
Institut Claudius Regaud
Toulouse, France
Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.